Graphite Bio is a gene-editing company developing therapeutics for a wide range of diseases. CRISPR technology offers the potential to rewrite genes and cure diseases following one therapeutic dose. Using their UltraHDR platform, Graphite is identifying CRISPR machinery that offers incredible precision in the gene-editing process and works to correct, replace and insert genes anywhere in the genome. Graphite’s proprietary technology has the potential to deliver individualized therapies going beyond personalized medicine. Currently, Graphite’s most advanced product, GPH101, is being tested to correct Sickle cell disease, with other programs focusing on Beta-thalassemia and AAT deficiency.

<p>Graphite Bio is a gene-editing company developing therapeutics for a wide range of diseases. CRISPR technology offers the potential to rewrite genes and cure diseases following one therapeutic dose. Using their UltraHDR platform, Graphite is identifying CRISPR machinery that offers incredible precision in the gene-editing process and works to correct, replace and insert genes anywhere in the genome. Graphite’s proprietary technology has the potential to deliver individualized therapies going beyond personalized medicine. Currently, Graphite’s most advanced product, GPH101, is being tested to correct Sickle cell disease, with other programs focusing on Beta-thalassemia and AAT deficiency.</p>


Graphite Bio

Founded: 2020
Location: South SF, CA
Employee range: 50 - 200
Drug types: HEM, GEN, LNG
Lead product: GPH101
Product link: https://graphitebio.com/pipeline/
Funding: $273M stock Jul 2021; $238M IPO Jun 2021; $150M B Mar 2021; $45M A Sep 2020
Investors: Versant Ventures

Short description:

Drug notes:

Long description:

Jobs: